4-(Pyridin-2-Yl)Aminocarbonylphenylboronic Acid Bulk Price Manufacturer 2026
- [Process Chemistry]: Optimized coupling routes ensure consistent >99% assay stability and minimal boronic acid homocoupling.
- [Supply Chain Logic]: Direct factory sourcing eliminates broker markups, securing tonnage quantities for commercial campaigns.
- [Market Trajectory]: Rising global demand for kinase inhibitor scaffolds drives volume requirements through 2026.
In the landscape of modern oncology drug development, the reliability of key starting materials dictates the success of clinical supply chains. 4-(Pyridin-2-yl)aminocarbonylphenylboronic acid (CAS: 850568-25-1) serves as a critical kinase inhibitor intermediate, specifically functioning as a vital acalabrutinib building block. For process chemists and procurement officers alike, understanding the technical nuances and commercial availability of this pyridinyl boronic acid derivative is essential for maintaining production schedules and cost efficiency.
As a premier global manufacturer, NINGBO INNO PHARMCHEM CO.,LTD. specializes in delivering this complex molecule with the batch-to-batch consistency required for GMP environments. The structural integrity of the boronic acid moiety is paramount, as degradation can lead to significant yield losses in downstream Suzuki-Miyaura couplings.
Bulk Pricing Tiers Versus Gram Scale Costs
The economics of purchasing 4-(Pyridin-2-yl)aminocarbonylphenylboronic acid vary significantly based on volume and purity specifications. While gram-scale quantities are suitable for initial route scouting, commercial manufacturing demands industrial purity at metric ton scales. The bulk price is influenced by the complexity of the synthesis route, particularly the protection and deprotection strategies required to maintain the integrity of the boronic acid group during amidation.
Procurement teams must evaluate the total cost of ownership, which includes not only the unit price but also the cost of reprocessing due to impurity profiles. Suppliers offering material with an assay of ≥99.0% typically command a premium, but this reduces the risk of downstream purification failures. The melting point range of 124-128°C is a key physical identifier used to verify batch quality before production begins.
Requesting Quotes From Global Manufacturer Partners
When vetting suppliers for critical intermediates, transparency regarding manufacturing capabilities is non-negotiable. Buyers should request detailed Certificate of Analysis (COA) documents that specify impurity levels, residual solvents, and heavy metal content. When sourcing high-purity 4-(Pyridin-2-yl)aminocarbonylphenylboronic acid, buyers should prioritize partners who can demonstrate scalable production capacity rather than mere trading capabilities.
NINGBO INNO PHARMCHEM CO.,LTD. offers factory-direct advantages, ensuring that technical queries regarding the [4-(pyridin-2-ylcarbamoyl)phenyl]boronic acid structure are handled by experienced chemists rather than sales agents. This direct line of communication facilitates faster resolution of technical discrepancies and ensures that custom synthesis requirements are met with precision.
Technical Specifications Overview
| Parameter | Specification |
|---|---|
| CAS Number | 850568-25-1 |
| Molecular Formula | C12H11BN2O3 |
| Molecular Weight | 242.04 g/mol |
| Assay (HPLC) | ≥ 99.0% |
| Melting Point | 124-128°C |
| Appearance | Solid (Off-white to Light Yellow) |
| Storage Condition | Keep Cold (2-8°C recommended for long-term) |
2026 Market Trends For Kinase Inhibitor Intermediates
The pharmaceutical market is projecting sustained growth for Bruton's tyrosine kinase (BTK) inhibitors through 2026. Consequently, the demand for specialized precursors like this aminocarbonyl phenylboronic acid is expected to rise. Supply chain resilience will be a key differentiator, as regulatory bodies increasingly scrutinize the origin and quality of starting materials.
Manufacturers who can guarantee REACH and TSCA compliance while maintaining competitive pricing will secure long-term contracts with major pharmaceutical developers. Strategic stockpiling of key intermediates is becoming a common practice to mitigate potential logistics disruptions. Ensuring a stable supply of this critical building block is essential for maintaining continuity in the production of life-saving oncology therapies.
To secure supply for upcoming production cycles, we recommend you contact our technical sales team for a batch-specific COA, SDS, or bulk pricing quote.